Roivant's brepocitinib succeeds in uveitis trials
Roivant's drug won approval for dermatomyositis and now posted positive results in two pivotal trials for non-infectious uveitis, setting up a 2027 filing.
Palanor Wire · composed from 3 outlets · every claim links to its sources
What happened
Roivant reported positive results in two pivotal trials for brepocitinib in non-infectious uveitis. 23 Brepocitinib won its first approval earlier for dermatomyositis. 12 Roivant plans to file for approval in 2027. 2
Why it matters
One analyst said the results suggest brepocitinib could be a "best-in-disease" medicine for inflammatory eye conditions. 1 The results mark a milestone in Roivant's effort to build an autoimmune franchise. 2
What to watch
Roivant's 2027 regulatory filing for uveitis. 2
Sources · 3
[1]Roivant's autoimmune drug succeeds in two pivotal trials, setting up 2027 filing
Endpoints News
[2]STAT+: Roivant says closely watched immune drug succeeded in new eye disease
STAT
[3]Roivant, continuing ascent, claims another victory for rare disease drug
BioPharma Dive
Matched signals
Lattice signals Numen pinned to this story at publish time.
No matched signals on this story.
Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.
Upgrade →On X right now
Top engagement posts about this topic, ranked by likes + retweets + quotes.
No high-engagement X posts captured for this topic. Either the topic is too quiet or the upstream API was unavailable when this article published.
Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.
Upgrade →Your read
How did this article land?
Three sliders. Optional comment. Anonymous is fine.
Open to anyone. One response per reader.